全文获取类型
收费全文 | 3897篇 |
免费 | 200篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 164篇 |
妇产科学 | 162篇 |
基础医学 | 320篇 |
口腔科学 | 80篇 |
临床医学 | 334篇 |
内科学 | 1247篇 |
皮肤病学 | 32篇 |
神经病学 | 238篇 |
特种医学 | 122篇 |
外科学 | 580篇 |
综合类 | 93篇 |
一般理论 | 1篇 |
预防医学 | 161篇 |
眼科学 | 169篇 |
药学 | 224篇 |
中国医学 | 18篇 |
肿瘤学 | 133篇 |
出版年
2024年 | 5篇 |
2023年 | 30篇 |
2022年 | 62篇 |
2021年 | 118篇 |
2020年 | 57篇 |
2019年 | 81篇 |
2018年 | 98篇 |
2017年 | 76篇 |
2016年 | 88篇 |
2015年 | 135篇 |
2014年 | 156篇 |
2013年 | 204篇 |
2012年 | 310篇 |
2011年 | 310篇 |
2010年 | 177篇 |
2009年 | 162篇 |
2008年 | 286篇 |
2007年 | 330篇 |
2006年 | 284篇 |
2005年 | 274篇 |
2004年 | 200篇 |
2003年 | 180篇 |
2002年 | 141篇 |
2001年 | 59篇 |
2000年 | 59篇 |
1999年 | 49篇 |
1998年 | 18篇 |
1997年 | 28篇 |
1996年 | 12篇 |
1995年 | 15篇 |
1994年 | 9篇 |
1993年 | 8篇 |
1992年 | 15篇 |
1991年 | 18篇 |
1990年 | 13篇 |
1989年 | 14篇 |
1988年 | 15篇 |
1987年 | 11篇 |
1986年 | 4篇 |
1985年 | 10篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 4篇 |
1973年 | 2篇 |
1956年 | 1篇 |
1932年 | 1篇 |
1931年 | 1篇 |
1929年 | 1篇 |
排序方式: 共有4156条查询结果,搜索用时 8 毫秒
71.
Early clinical studies investigating the role of angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart failure unexpectedly demonstrated a possible reduction in coronary heart disease endpoints. Two large scale clinical trials, HOPE and EUROPA, both studies in patients with coronary artery disease (CAD) but without clinical evidence of heart failure, showed a highly significant improvement in coronary heart disease outcomes on treatment with ramipril and perindopril, respectively, in contrast, in a similar population, PEACE was unable to demonstrate such benefit with trandolapril. Meta-analyses of all trials involving ACE-inhibitors showed a highly significant improvement in coronary heart disease endpoints. Current ESC guidelines recommend ACE-inhibitor therapy in CAD patients with co-existing indications for ACE-inhibitors, such as hypertension, heart failure, left ventricular dysfunction, prior MI was left ventricular dysfunction, or diabetes (class I, level of evidence A). These guidelines also recommend ACE-inhibitor therapy in all patients with angina and proven coronary disease (class IIa, level of evidence B). However, in angina patients without independent indication for ACE-inhibitor treatment, the anticipated benefit should be weighted against the costs and risks of side effects; in these patients, only agents and doses of proven efficacy for secondary prevention should be employed. 相似文献
72.
Background and study aims
Occult hepatitis B infection (OBI) is known to be mostly prevalent in chronic hepatitis C (CHC) patients and OBI reactivation might be life-threatening in patients undergoing interferon (IFN)-free direct acting antiviral (DAA) therapy. As previous studies have revealed a relationship between OBI and non-response to IFN-based antiviral therapy, the aim of the current study was to determine if there was a higher prevalence of OBI in IFN non-responders than responders.Patients and Methods
This retrospective cross-sectional study was conducted in CHC patients who had previously received IFN-based antiviral therapy. Serum samples of 100 HBsAg negative CHC patients were tested for HBV DNA, anti-HBc IgG, anti-HBs, ALT and AST. The presence of OBI was compared between 50 IFN responders and 50 IFN non-responders. Patients with a history of previous HBV infection, patients with evidence of cirrhosis and patients who had received IFN therapy within the last one year were excluded from the study.Results
Anti-HBc IgG positivity was determined in 53% of the patients. HBV DNA positivity, indicating OBI was determined in 1 (1%) patient. This patient was anti-HBc IgG positive, anti-HBs negative, ALT and AST levels were normal. The HBV DNA and anti-HBc IgG positivity rates were higher in the non-responder group than in the responder group, but the difference was not statistically significant (p?=?0.31 and p?=?0.07 respectively).Conclusion
According to the results of this study, the prevalence of OBI is lower than expected amongst CHC patients in Turkey and it may not be necessary to apply routine screening to IFN non-responders for OBI infection before DAA therapy. However, there is a need for multicentre studies with larger patient series. 相似文献73.
An overview of eight randomized controlled trials of tissue-type plasminogen activator (Alteplase or Duteplase) and 10 of anisoylated plasminogen streptokinase activator complex (Anistreplase) showed that the odds of early death were reduced by 29% by tissue-type plasminogen activator and 46% by anisoylated plasminogen streptokinase activator complex, with overlapping 95% confidence intervals. Although the beneficial effects of both agents are consistent and are strengthened when all the trials are considered together, the available data do not permit comparisons of the relative efficacy of these two agents with each other or with streptokinase. 相似文献
74.
75.
76.
Cucurbit chlorotic yellows virus (CCYV) and Cucurbit yellow stunting disorder virus (CYSDV) are whitefly-transmitted criniviruses infecting cucurbit crops inducing similar symptoms. Single and multiplex RT-PCR protocols were developed and evaluated on cucurbit samples collected from commercial greenhouses. Primers and probes were designed from the highly conserved heat shock protein 70 homolog (Hsp70h) gene. Conventional RT-PCR and multiplex RT-PCR assays showed high specificity and suitability for routine screening. TaqMan-based quantitative real-time RT-PCR (RT-qPCR) protocols were also developed for the detection and quantitation of both viruses occurring in single or mixed infection. The assays proved to be highly specific with no cross amplification. RT-qPCR assays showed a 100–1000 times improved sensitivity over conventional RT-PCR. Virus titers in mixed infections were compared to singly infected plants by RT-qPCR. CYSDV and CCYV titers decreased in double infected plants. This paper reports highly specific conventional RT-PCR and quantitative real-time PCR assays for detection, quantitation and differentiation between two closely related cucurbit-infecting criniviruses. 相似文献
77.
78.
79.
80.